# List of therapeutic monoclonal antibodies

Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.
The abbreviations in the column Type are as follows:
* mab: whole monoclonal antibody
* Fab: fragment, antigen-binding (one arm)
** F(ab')$_2$: fragment, antigen-binding, including hinge region (both arms)
** Fab': fragment, antigen-binding, including hinge region (one arm)
* Variable fragments:
** scFv: single-chain variable fragment
** di-scFv: dimeric single-chain variable fragment
** sdAb: single-domain antibody
* BsAb: bispecific monoclonal antibody:
** 3funct: trifunctional antibody
** BiTE: bi-specific T-cell engager
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
| Name | Brand name | Type | Source | Target | Approved | Use |
| 3F8 | | mab | mouse | GD2 ganglioside | | neuroblastoma |
| Abagovomab | | mab | mouse | CA-125 (imitation) | | ovarian cancer |
| Abciximab | ReoPro | Fab | chimeric | CD41 (integrin alpha-IIb) | Y | platelet aggregation inhibitor |
| Abituzumab | | mab | humanized | CD51 | | cancer |
| Abrezekimab | | Fab | humanized | IL-13 | | |
| Abrilumab | | mab | human | integrin α$_4$ β$_7$ | | inflammatory bowel disease, ulcerative colitis, Crohn's disease |
| Actoxumab | | mab | human | Clostridioides difficile | | Clostridioides difficile colitis |
| Adalimumab | Humira | mab | human | TNF-α | Y | rheumatoid arthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, hemolytic disease of the newborn |
| Adecatumumab | | mab | human | EpCAM | | prostate and breast cancer |
| Aducanumab | Aduhelm | mab | human | Amyloid beta | Y | Alzheimer's disease |
| Afasevikumab | | mab | human | IL-17A, IL-17F | | multiple sclerosis |
| Afelimomab | | F(ab')$_2$ | mouse | TNF-α | | sepsis |
| Alacizumab pegol | | F(ab')$_2$ | humanized | VEGFR2 | | cancer |
| Alemtuzumab | Lemtrada, Campath | mab | humanized | CD52 | Y | multiple sclerosis |
| Alirocumab | Praluent | mab | human | PCSK9 | Y | hypercholesterolemia |
| Altumomab pentetate | Hybri-ceaker | mab | mouse | Carcinoembryonic antigen (CEA) | | colorectal cancer (diagnosis) |
| Amatuximab | | mab | chimeric | mesothelin | | cancer |
| Amivantamab | Rybrevant | BsAb | human | Epidermal growth factor receptor (EGFR), cMet | Y | non-small cell lung cancer |
| Anatumomab mafenatox | | Fab | mouse | Tumor-associated glycoprotein 72 (TAG-72) | | non-small cell lung cancer |
| Andecaliximab | | mab | chimeric | gelatinase B | | gastric cancer or gastroesophageal junction adenocarcinoma |
| Anetumab ravtansine | | mab | human | mesothelin (MSLN) | | cancer |
| Anifrolumab | Saphnelo | mab | human | IFN-α/β receptor | Y | systemic lupus erythematosus |
| Ansuvimab | Ebanga | mab | human | Ebola virus glycoprotein | Y | treatment of Zaire ebolavirus (Ebola virus) |
| Anrukinzumab (= IMA-638) | | mab | humanized | IL-13 | | asthma |
| Apolizumab | | mab | humanized | HLA-DR | | hematological cancers |
| Aprutumab ixadotin | | mab | human | FGFR2 | | |
| Arcitumomab | CEA-Scan | Fab' | mouse | Carcinoembryonic antigen (CEA) | | gastrointestinal cancers (diagnosis) |
| Ascrinvacumab | | mab | human | activin receptor-like kinase 1 | | cancer |
| Aselizumab | | mab | humanized | L-selectin (CD62L) | | severely injured patients |
| Atezolizumab | Tecentriq | mab | humanized | PD-L1 | Y | cancer |
| Atidortoxumab | | mab | human | Staphylococcus aureus alpha toxin | | |
| Atinumab | | mab | human | RTN4 | | |
| Atoltivimab | | mab | human | Ebola virus glycoprotein | | part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus) |
| Atoltivimab/maftivimab/odesivimab | Inmazeb | mab | human | | Y | treatment of Zaire ebolavirus (Ebola virus) |
| Atorolimumab | | mab | human | Rhesus factor | | hemolytic disease of the newborn |
| Avelumab | Bavencio | mab | human | PD-L1 | Y | cancer |
| Axatilimab | Niktimvo | mab | humanized | CSF1R | Y | chronic graft-versus-host disease |
| Azintuxizumab vedotin | | mab | chimeric/ humanized | CD319 | | cancer |
| Bamlanivimab | | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | US emergency use authorization (EUA) when used with etesevimab | COVID-19 |
| Bapineuzumab | | mab | humanized | β-amyloid | | Alzheimer's disease |
| Basiliximab | Simulect | mab | chimeric | CD25 (α chain of IL-2 receptor) | Y | prevention of organ transplant rejections |
| Bavituximab | | mab | chimeric | phosphatidylserine | | cancer, viral infections |
| BCD-100 | | | human | PD-1 | | melanoma |
| Bebtelovimab | | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | US emergency use authorization (EUA) | COVID-19 |
| Bectumomab | LymphoScan | Fab' | mouse | CD22 | | non-Hodgkin's lymphoma (detection) |
| Bedinvetmab | Librela | mab | veterinary | nerve growth factor (NGF) | Y | pain associated with osteoarthritis in dogs |
| Begelomab | | mab | mouse | DPP4 | | |
| Belantamab mafodotin | Blenrep | mab | humanized | B-cell maturation antigen (BCMA) | Y (Withdrawn) | relapsed or refractory multiple myeloma |
| Belimumab | Benlysta | mab | human | B-cell activating factor (BAFF) | Y | systemic lupus erythematosus without renal or CNS involvement |
| Bemarituzumab | | mab | humanized | FGFR2 | | gastric cancer or gastroesophageal junction adenocarcinoma |
| Benralizumab | Fasenra | mab | humanized | CD125 | Y | asthma |
| Berlimatoxumab | | mab | human | Staphylococcus aureus bi-component leukocidin | | |
| Bermekimab | Xilonix | mab | human | IL-1α | | colorectal cancer |
| Bersanlimab | | mab | human | ICAM-1 | | |
| Bertilimumab | | mab | human | CCL11 (eotaxin-1) | | severe allergic disorders |
| Besilesomab | Scintimun | mab | mouse | Carcinoembryonic antigen (CEA)-related antigen | | inflammatory lesions and metastases (detection) |
| Bevacizumab | Avastin | mab | humanized | VEGF-A | Y | metastatic cancer, retinopathy of prematurity |
| Bezlotoxumab | Zinplava | mab | human | Clostridioides difficile | Y | Clostridioides difficile colitis |
| Biciromab | FibriScint | Fab' | mouse | fibrin II, beta chain | | thromboembolism (diagnosis) |
| Bimagrumab | | mab | human | ACVR2B | | myostatin inhibitor |
| Bimekizumab | Bimzelx | mab | humanized | IL-17A, IL-17F, IL-17AF | Y | psoriasis |
| Birtamimab | | mab | chimeric | serum amyloid A protein | | amyloidosis |
| Bivatuzumab | | mab | humanized | CD44 v6 | | squamous cell carcinoma |
| Bleselumab | | mab | human | CD40 | | organ transplant rejection |
| Blinatumomab | Blincyto | BiTE | mouse | CD19 | Y | pre-B Acute lymphoblastic leukemia (ALL) (CD19+) |
| Blontuvetmab | Blontress | mab | veterinary | CD20 | | |
| Blosozumab | | mab | humanized | SOST | | osteoporosis |
| Bococizumab | | mab | humanized | PCSK9 | | dyslipidemia |
| Brazikumab | | mab | human | IL-23 | | Crohn's disease |
| Brentuximab vedotin | Adcentris | mab | chimeric | CD30 (TNFRSF8) | Y | Hodgkin's lymphoma, anaplastic large-cell lymphoma |
| Briakinumab | | mab | human | IL-12, IL-23 | | psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis |
| Brodalumab | Siliq | mab | human | IL-17 | Y | Plaque psoriasis |
| Brolucizumab | Beovu | scFv | humanized | vascular endothelial growth factor A (VEGFA) | Y | wet age-related macular degeneration |
| Brontictuzumab | | mab | humanized | Notch 1 | | cancer |
| Burosumab | Crysvita | mab | human | FGF 23 | Y | X-linked hypophosphatemia |
| Cabiralizumab | | mab | humanized | CSF1R | | metastatic pancreatic cancer |
| Camidanlumab tesirine | | mab | human | CD25 (α chain of IL-2 receptor) | | B-cell Hodgkin's lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia |
| Camrelizumab | | mab | humanized | PD-1 | | hepatocellular carcinoma |
| Canakinumab | Ilaris | mab | human | IL-1 | Y | cryopyrin-associated periodic syndrome, Yao's Syndrome, Adult Onset Still's Disease |
| Cantuzumab mertansine | | mab | humanized | CanAg (a glycoform of MUC1) | | colorectal cancer etc. |
| Cantuzumab ravtansine | | mab | humanized | CanAg (a glycoform of MUC1) | | cancers |
| Caplacizumab | Cablivi | sdAb | humanized | VWF | Y | thrombotic thrombocytopenic purpura, thrombosis |
| Casirivimab | | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | Yes when used with imdevimab | COVID-19 |
| Capromab | Prostascint | mab | mouse | Glutamate carboxypeptidase II | Y | prostate cancer (detection) |
| Carlumab | | mab | human | MCP-1 | | oncology/immune indications |
| Carotuximab | | mab | chimeric | endoglin | | angiosarcoma |
| Catumaxomab | Removab | 3funct | rat/mouse hybrid | EpCAM, CD3 | Y | ovarian cancer, malignant ascites, gastric cancer |
| cBR96-doxorubicin immunoconjugate | | mab | humanized | Lewis-Y antigen | | cancer |
| Cedelizumab | | mab | humanized | CD4 | | prevention of organ transplant rejections, treatment of autoimmune diseases |
| Cemiplimab | Libtayo | mab | human | PD-1 | Y | cutaneous squamous cell carcinoma |
| Cergutuzumab amunaleukin | | mab | humanized | IL-2 | | cancer |
| Certolizumab pegol | Cimzia | Fab' | humanized | TNF-α | Y | Crohn's disease, rheumatoid arthritis, axial spondyloarthritis, psoriasis arthritis |
| Cetrelimab | | mab | human | PD-1 | | cancer |
| Cetuximab | Erbitux | mab | chimeric | Epidermal growth factor receptor (EGFR) | Y | metastatic colorectal cancer and head and neck cancer |
| Cibisatamab | | mab | humanized | CEACAM5 | | cancer |
| Cilgavimab | | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | US emergency use authorization (EUA) when used with tixagevimab | COVID-19 |
| Cirmtuzumab | | | humanized | ROR1 | | chronic lymphocytic leukemia |
| Citatuzumab bogatox | | Fab | humanized | EpCAM | | ovarian cancer and other solid tumors |
| Cixutumumab | | mab | human | IGF-1 receptor (CD221) | | solid tumors |
| Clazakizumab | | mab | humanized | IL-6 | | rheumatoid arthritis |
| Clenoliximab | | mab | chimeric | CD4 | | rheumatoid arthritis |
| Clivatuzumab tetraxetan | hPAM4-Cide | mab | humanized | MUC1 | | pancreatic cancer |
| Codrituzumab | | mab | humanized | glypican 3 | | cancer |
| Cofetuzumab pelidotin | | mab | humanized | PTK7 | | cancer |
| Coltuximab ravtansine | | mab | chimeric | CD19 | | cancer |
| Conatumumab | | mab | human | TRAIL-R2 | | cancer |
| Concizumab | Alhemo | mab | humanized | tissue factor pathway inhibitor (TFPI) | Y | bleeding with hemophilia |
| Cosfroviximab | ZMapp | mab | chimeric | ebolavirus glycoprotein | | Ebola virus |
| Cosibelimab | Unloxcyt | mab | human | Programmed death ligand-1 (PD-L1) | Y | cutaneous squamous cell carcinoma |
| Crenezumab | | mab | humanized | β-amyloid (1-40 and 1-42) | | Alzheimer's disease |
| Crizanlizumab | Adakveo | mab | humanized | selectin P | Y | sickle-cell disease |
| Crotedumab | | mab | human | glucagon receptor (GCGR) | | diabetes |
| Crovalimab | Piasky | mab | humanized | C5 | Y | paroxysmal nocturnal hemoglobinuria |
| CR6261 | | mab | human | Hemagglutinin (influenza) | | infectious disease/influenza A |
| Cusatuzumab | | mab | humanized | CD70 | | cancer |
| Dacetuzumab | | mab | humanized | CD40 | | hematologic cancers |
| Daclizumab | Zenapax | mab | humanized | CD25 (α chain of IL-2 receptor) | Y | prevention of organ transplant rejections, multiple sclerosis |
| Dalotuzumab | | mab | humanized | IGF-1 receptor (CD221) | | cancer etc. |
| Dapirolizumab pegol | | mab | humanized | CD154 (CD40L) | | |
| Daratumumab | Darzalex | mab | human | CD38 | Y | multiple myeloma |
| Dectrekumab | | mab | human | IL-13 | | |
| Demcizumab | | mab | humanized | DLL4 | | cancer |
| Denintuzumab mafodotin | | mab | humanized | CD19 | | cancer |
| Denosumab | Prolia | mab | human | RANKL | Y | osteoporosis, bone metastases etc. |
| Depatuxizumab mafodotin | | mab | chimeric/ humanized | EGFR | | glioblastoma |
| Derlotuximab biotin | | mab | chimeric | histone complex | | recurrent glioblastoma multiforme |
| Detumomab | | mab | mouse | B-lymphoma cell | | lymphoma |
| Dezamizumab | | mab | humanized | serum amyloid P component | | |
| Dinutuximab | Unituxin | mab | chimeric | GD2 ganglioside | Y | neuroblastoma |
| Dinutuximab beta | Qarziba | mab | chimeric | GD2 ganglioside | Y | neuroblastoma |
| Diridavumab | | mab | human | Hemagglutinin (influenza) | | influenza A |
| Divozilimab | Ivlizi | mab | humanized | CD20 | Y (Russia) | multiple sclerosis |
| Domagrozumab | | mab | humanized | GDF-8 | | Duchenne muscular dystrophy |
| Donanemab | Kisunla | mab | humanized | Amyloid beta | Y | Alzheimer's disease |
| Dorlimomab aritox | | F(ab')$_2$ | mouse | | | |
| Dostarlimab | Jemperli | mab | humanized | PCDP1 | Y | endometrial cancer |
| Drozitumab | | mab | human | DR5 | | cancer etc. |
| DS-8201 | | | humanized | HER2 | | gastric or gastroesophageal junction adenocarcinoma |
| Duligotuzumab | | mab | humanized | ERBB3 (HER3) | | testicular cancer |
| Dupilumab | Dupixent | mab | human | IL-4Rα | Y | atopic dermatitis, asthma, nasal polyps |
| Durvalumab | Imfinzi | mab | human | PD-L1 | Y | cancer |
| Dusigitumab | | mab | human | IGF-2 | | B-cell malignancies |
| Duvortuxizumab | | scFv | chimeric/ humanized | CD19, CD3E | | cancer |
| Ecromeximab | | mab | chimeric | GD3 ganglioside | | malignant melanoma |
| Eculizumab | Soliris | mab | humanized | C5 | Y | paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome |
| Edobacomab | | mab | mouse | endotoxin | | sepsis caused by Gram-negative bacteria |
| Edrecolomab | Panorex | mab | mouse | EpCAM | | colorectal carcinoma |
| Efalizumab | Raptiva | mab | humanized | LFA-1 (CD11a) | | psoriasis (blocks T-cell migration) |
| Efungumab | Mycograb | scFv | human | Hsp90 | | invasive Candida infection |
| Eldelumab | | mab | human | CXCL10 (IP-10) | | Crohn's disease, ulcerative colitis |
| Elezanumab | | mab | human | repulsive guidance molecule A (RGMA) | | spinal cord injury and multiple sclerosis |
| Elgemtumab | | mab | human | ERBB3 (HER3) | | cancer |
| Elotuzumab | Empliciti | mab | humanized | SLAMF7 | Y | multiple myeloma |
| Elsilimomab | | mab | mouse | IL-6 | | |
| Emactuzumab | | mab | humanized | CSF1R | | cancer |
| Emapalumab | Gamifant | mab | human | IFN-γ | Y | hemophagocytic lymphohistiocytosis |
| Emibetuzumab | | mab | humanized | HGFR | | cancer |
| Emicizumab | Hemlibra | BsAb | humanized | activated F9, F10 | Y | haemophilia A |
| Enapotamab vedotin | | mab | human | AXL | | cancer |
| Enavatuzumab | | mab | humanized | TWEAK receptor | | cancer etc. |
| Enfortumab vedotin | Padcev | mab | human | nectin-4 | Y | urothelial cancer |
| Enlimomab pegol | | mab | mouse | ICAM-1 (CD54) | | |
| Enoblituzumab | | mab | humanized | CD276 | | cancer |
| Enokizumab | | mab | humanized | IL-9 | | asthma |
| Enoticumab | | mab | human | DLL4 | | |
| Ensituximab | | mab | chimeric | MUC5AC | | cancer |
| Epcoritamab | Epkinly | BiTE | humanized | CD3, CD20 | Y | diffuse large B-cell lymphoma |
| Epitumomab cituxetan | | mab | mouse | episialin | | |
| Epratuzumab | | mab | humanized | CD22 | | cancer, systemic lupus erythematosus (SLE) |
| Eptinezumab | Vyepti | mab | humanized | calcitonin gene-related peptide | Y | migraine |
| Erenumab | Aimovig | mab | human | calcitonin gene-related peptide receptor (CGRP) | Y | migraine |
| Erlizumab | | F(ab')$_2$ | humanized | ITGB2 (CD18) | | heart attack, stroke, traumatic shock |
| Ertumaxomab | Rexomun | 3funct | rat/mouse hybrid | HER2/neu, CD3 | Y | breast cancer etc. |
| Etaracizumab | Abegrin | mab | humanized | integrin α$_v$β$_3$ | Y | melanoma, prostate cancer, ovarian cancer etc. |
| Etesevimab | | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | US emergency use authorization (EUA) when used with bamlanivimab | COVID-19 |
| Etigilimab | | mab | humanized | TIGIT | | |
| Etrolizumab | | mab | humanized | integrin β$_7$ | | inflammatory bowel disease |
| Evinacumab | Evkeeza | mab | human | angiopoietin 3 | Y | dyslipidemia |
| Evolocumab | Repatha | mab | human | PCSK9 | Y | hypercholesterolemia |
| Exbivirumab | | mab | human | hepatitis B surface antigen | | hepatitis B |
| Fanolesomab | NeutroSpec | mab | mouse | CD15 | | appendicitis (diagnosis) |
| Faralimomab | | mab | mouse | IFN receptor | | |
| Faricimab | Vabysmo | mab | humanized | VEGF-A and Ang-2 | Y | angiogenesis, ocular vascular diseases |
| Farletuzumab | | mab | humanized | folate receptor 1 | | ovarian cancer |
| Fasinumab | | mab | human | nerve growth factor (NGF) | | acute sciatic pain |
| FBTA05 | Lymphomun | 3funct | rat/mouse hybrid | CD20 | | chronic lymphocytic leukaemia |
| Felvizumab | | mab | humanized | respiratory syncytial virus | | respiratory syncytial virus infection |
| Fezakinumab | | mab | human | IL-22 | | rheumatoid arthritis, psoriasis |
| Fibatuzumab | | mab | humanized | ephrin receptor A3 | | |
| Ficlatuzumab | | mab | humanized | Hepatocyte growth factor (HGF) | | cancer etc. |
| Figitumumab | | mab | human | IGF-1 receptor (CD221) | | adrenocortical carcinoma, non-small cell lung carcinoma etc. |
| Firivumab | | mab | human | Hemagglutinin (influenza) | | |
| Flanvotumab | | mab | human | TYRP1 (glycoprotein 75) | | melanoma |
| Fletikumab | | mab | human | IL-20 | | rheumatoid arthritis |
| Flotetuzumab | | di-scFv | humanized | IL-3 receptor | | hematological malignancies |
| Fontolizumab | HuZAF | mab | humanized | IFN-γ | | Crohn's disease etc. |
| Foralumab | | mab | human | CD3E | | |
| Foravirumab | | mab | human | rabies virus glycoprotein | | rabies (prophylaxis) |
| Fremanezumab | Ajovy | mab | humanized | calcitonin gene-related peptide alpha and beta | Y | migraine |
| Fresolimumab | | mab | human | TGF-β | | idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer |
| Frovocimab | | mab | humanized | PCSK9 | | hypercholesterolemia |
| Frunevetmab | Solensia | mab | veterinary | nerve growth factor (NGF) | Y | pain associated with osteoarthritis in cats |
| Fulranumab | | mab | human | nerve growth factor (NGF) | | pain |
| Futuximab | | mab | chimeric | Epidermal growth factor receptor (EGFR) | | cancer |
| Galcanezumab | Emgality | mab | humanized | calcitonin | Y | migraine |
| Galiximab | | mab | chimeric | CD80 | | B-cell lymphoma |
| Gancotamab | | scFv | human | HER2/neu | | cancer |
| Ganitumab | | mab | human | IGF-1 receptor (CD221) | | cancer |
| Gantenerumab | | mab | human | β-amyloid (1-40 and 1-42) | | Alzheimer's disease |
| Garadacimab | Andembry | mab | human | Coagulation factor XIIa | Y | hereditary angioedema |
| Gatipotuzumab | | mab | humanized | MUC1 | | cancer |
| Gavilimomab | | mab | mouse | CD147 (basigin) | | graft versus host disease |
| Gedivumab | | mab | human | Hemagglutinin (influenza) | | |
| Gemtuzumab ozogamicin | Mylotarg | mab | humanized | CD33 | Y | acute myelogenous leukemia |
| Gevokizumab | | mab | humanized | IL-1β | | diabetes etc. |
| Gilvetmab | | mab | veterinary | PCDC1 | | |
| Gimsilumab | | mab | human | CSF2 | | rheumatoid arthritis |
| Girentuximab | Rencarex | mab | chimeric | carbonic anhydrase 9 (CA-IX) | | clear cell renal cell carcinoma |
| Glembatumumab vedotin | | mab | human | GPNMB | | melanoma, breast cancer |
| Glofitamab | Columvi | BsAb | humanized | CD20, CD3 | Y | diffuse large B-cell lymphoma |
| Golimumab | Simponi | mab | human | TNF-α | Y | rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis |
| Gomiliximab | | mab | chimeric | CD23 (IgE receptor) | | allergic asthma |
| Gosuranemab | | mab | humanized | tau protein | | progressive supranuclear palsy |
| Guselkumab | Tremfya | mab | human | IL-23 | Y | psoriasis |
| Ianalumab | | mab | human | BAFF-R | | autoimmune hepatitis |
| Ibalizumab | Trogarzo | mab | humanized | CD4 | Y | HIV infection |
| Sintilimab | | | human | PD-1 | | squamous cell non-small cell lung cancer |
| Ibritumomab tiuxetan | Zevalin | mab | mouse | CD20 | Y | non-Hodgkin's lymphoma |
| Icrucumab | | mab | human | VEGFR-1 | | cancer etc. |
| Idarucizumab | Praxbind | mab | humanized | dabigatran | Y | reversal of anticoagulant effects of dabigatran |
| Ifabotuzumab | | mab | humanized | EPHA3 | | glioblastoma multiforme |
| Igovomab | Indimacis-125 | F(ab')$_2$ | mouse | CA-125 | | ovarian cancer (diagnosis) |
| Iladatuzumab vedotin | | mab | humanized | CD79B | | cancer |
| Imalumab | | mab | human | macrophage migration inhibitory factor (MIF) | | cancer |
| Imaprelimab | | mab | humanized | melanoma cell adhesion molecule (MCAM) | | |
| Imciromab | Myoscint | mab | mouse | cardiac myosin | Y | cardiac imaging |
| Imdevimab | | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | Yes when used with casirivimab | COVID-19 |
| Imgatuzumab | | mab | humanized | Epidermal growth factor receptor (EGFR) | | cancer |
| Inclacumab | | mab | human | selectin P | | cardiovascular disease |
| Indatuximab ravtansine | | mab | chimeric | SDC1 | | cancer |
| Indusatumab vedotin | | mab | human | GUCY2C | | cancer |
| Inebilizumab | Uplizna | mab | humanized | CD19 | Y | cancer, systemic sclerosis, multiple sclerosis |
| Infliximab | Remicade | mab | chimeric | TNF-α | Y | rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis |
| Intetumumab | | mab | human | CD51 | | solid tumors (prostate cancer, melanoma) |
| Inolimomab | | mab | mouse | CD25 (α chain of IL-2 receptor) | | graft versus host disease |
| Inotuzumab ozogamicin | Besponsa | mab | humanized | CD22 | Y | Acute lymphoblastic leukemia (ALL) |
| Ipilimumab | Yervoy | mab | human | CD152 | Y | melanoma |
| Iomab-B | | | mouse | CD45 | | ablation of bone marrow |
| Iratumumab | | mab | human | CD30 (TNFRSF8) | | Hodgkin's lymphoma |
| Isatuximab | Sarclisa | mab | chimeric | CD38 | Y | multiple myeloma |
| Iscalimab | | mab | human | CD40 | | |
| Istiratumab | | mab | human | IGF-1 receptor (CD221) | | advanced solid tumors |
| Itolizumab | Alzumab | mab | humanized | CD6 | Y | psoriasis |
| Ixekizumab | Taltz | mab | humanized | IL-17A | Y | autoimmune diseases |
| KappaMAB | | mab | mouse | Kappa Myeloma Antigen (KMA) | | multiple myeloma |
| Keliximab | | mab | chimeric | CD4 | | chronic asthma |
| Labetuzumab | CEA-Cide | mab | humanized | Carcinoembryonic antigen (CEA) | | colorectal cancer |
| Lacnotuzumab | | mab | humanized | CSF1, macrophage colony stimulating factor (MCSF) | | cancer |
| Ladiratuzumab vedotin | | mab | humanized | LIV-1 | | cancer |
| Lampalizumab | | Fab | humanized | Complement factor D (CFD) | | geographic atrophy secondary to age-related macular degeneration |
| Lanadelumab | Takhzyro | mab | human | kallikrein | Y | angioedema |
| Landogrozumab | | mab | humanized | GDF-8 | | muscle wasting disorders |
| Laprituximab emtansine | | mab | chimeric | epidermal growth factor receptor (EGFR) | | |
| Larcaviximab | | mab | chimeric | ebolavirus glycoprotein | | Ebola virus |
| Lebrikizumab | | mab | humanized | IL-13 | | asthma |
| Lecanemab | Leqembi | mab | humanized | β-amyloid | Y | Alzheimer's disease |
| Lemalesomab | | mab | mouse | NCA-90 (granulocyte antigen) | | diagnostic agent |
| Lendalizumab | | mab | humanized | C5 | | |
| Lenvervimab | | mab | humanized | hepatitis B surfage antigen | | hepatitis B |
| Lenzilumab | | mab | human | CSF2 | | chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia |
| Lerdelimumab | | mab | human | TGF-β2 | | reduction of scarring after glaucoma surgery |
| Leronlimab | | mab | humanized | CCR5 | | breast cancer, HIV |
| Lesofavumab | | mab | human | Hemagglutinin (influenza) | | |
| Letolizumab | | scFv | humanized | tumor necrosis factor related activation protein (TRAP) | | inflammatory diseases |
| Lexatumumab | | mab | human | TRAIL-R2 | | cancer |
| Libivirumab | | mab | human | hepatitis B surface antigen | | hepatitis B |
| Lifastuzumab vedotin | | mab | humanized | phosphate-sodium co-transporter | | cancer |
| Ligelizumab | | mab | humanized | IGHE | | severe asthma, chronic spontaneous urticaria |
| Loncastuximab tesirine | Zynlonta | mab | chimeric | CD19 | Y | relapsed or refractory large B-cell lymphoma |
| Losatuxizumab vedotin | | mab | chimeric/ humanized | epidermal growth factor receptor (EGFR), ERBB1 (HER1) | | cancer |
| Lilotomab satetraxetan | | mab | mouse | CD37 | | cancer |
| Lintuzumab | | mab | humanized | CD33 | | cancer |
| Linvoseltamab | | BsAb | human | CD3 and B-cell maturation antigen (BCMA) | | multiple myeloma |
| Lirilumab | | mab | human | KIR2D | | solid and hematological cancers |
| Lodelcizumab | | mab | humanized | PCSK9 | | hypercholesterolemia |
| Lokivetmab | Cytopoint | mab | veterinary | Canis lupus familiaris IL31 | Y | clinical signs of atopic dermatitis in dogs |
| Lorvotuzumab mertansine | | mab | humanized | CD56 | | cancer |
| Lucatumumab | | mab | human | CD40 | | multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma |
| Lulizumab pegol | | mab | humanized | CD28 | | autoimmune diseases |
| Lumiliximab | | mab | chimeric | CD23 (IgE receptor) | | chronic lymphocytic leukemia |
| Lumretuzumab | | mab | humanized | ERBB3 (HER3) | | cancer |
| Lupartumab | | mab | human | | | |
| Lupartumab amadotin | | mab | human | LYPD3 | | |
| Lutikizumab | | mab | humanized | IL-1α | | |
| Maftivimab | | mab | human | | | part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus) |
| Mapatumumab | | mab | human | TRAIL-R1 | | cancer |
| Margetuximab | Margenza | mab | humanized | HER2 | Y | breast cancer |
| Marstacimab | Hympavzi | mab | human | tissue factor pathway inhibitor (TFPI) | Y | bleeding with hemophilia |
| Maslimomab | | | mouse | T-cell receptor | | |
| Mavrilimumab | | mab | human | GMCSF receptor α-chain | | rheumatoid arthritis |
| Matuzumab | | mab | humanized | Epidermal growth factor receptor (EGFR) | | colorectal, lung and stomach cancer |
| Mepolizumab | Bosatria | mab | humanized | IL-5 | Y | asthma and white blood cell diseases |
| Metelimumab | | mab | human | TGF-β1 | | systemic scleroderma |
| Milatuzumab | | mab | humanized | CD74 | | multiple myeloma and other hematological malignancies |
| Minretumomab | | mab | mouse | TAG-72 | | tumor detection (and therapy?) |
| Mirikizumab | Omvoh | mab | humanized | IL-23 | Y | ulcerative colitis |
| Mirvetuximab soravtansine | Elahere | mab | chimeric | folate receptor alpha | Y | ovarian cancer |
| Mitumomab | | mab | mouse | GD3 ganglioside | | small cell lung carcinoma |
| Modotuximab | | mab | chimeric | EGFR extracellular domain III | | cancer |
| Mogamulizumab | Poteligeo | mab | humanized | CCR4 | Y | adult T-cell leukemia/lymphoma |
| Monalizumab | | mab | humanized | NKG2A | | rheumatoid arthritis, gynecologic malignancies, and other cancers |
| Morolimumab | | mab | human | Rhesus factor | | |
| Mosunetuzumab | Lunsumio | BiTE | humanized | CD3E, MS4A1, CD20 | Y | follicular lymphoma |
| Motavizumab | Numax | mab | humanized | respiratory syncytial virus | | respiratory syncytial virus (prevention) |
| Moxetumomab pasudotox | Lumoxiti | mab | mouse | CD22 | Y | hairy cell leukemia |
| Muromonab-CD3 | Orthoclone OKT3 | mab | mouse | CD3 | | prevention of organ transplant rejections |
| Nacolomab tafenatox | | Fab | mouse | C242 antigen | | colorectal cancer |
| Namilumab | | mab | human | CSF2 | | |
| Naptumomab estafenatox | | Fab | mouse | 5T4 | | non-small cell lung carcinoma, renal cell carcinoma |
| Naratuximab emtansine | | mab | chimeric | CD37 | | |
| Narnatumab | | mab | human | MST1R (aka RON) | | cancer |
| Natalizumab | Tysabri | mab | humanized | integrin α$_4$ | Y | multiple sclerosis, Crohn's disease |
| Navicixizumab | | mab | chimeric/ humanized | DLL4 and VEGFA | | cancer |
| Navivumab | | mab | human | Hemagglutinin (influenza) | | |
| Naxitamab | Danyelza | | humanized | c-Met | Y | high-risk neuroblastoma and refractory osteomedullary disease |
| Nebacumab | | mab | human | endotoxin | | sepsis |
| Necitumumab | Portrazza | mab | human | Epidermal growth factor receptor (EGFR) | Y | non-small cell lung carcinoma |
| Nemolizumab | | mab | humanized | IL-31 receptor A | | eczema |
| NEOD001 | | | humanized | amyloid | | primary systemic amyloidosis |
| Nerelimomab | | mab | mouse | TNF-α | | |
| Nesvacumab | | mab | human | angiopoietin 2 | | cancer |
| Netakimab | Efleira | mab | humanized | IL-17A | Y (Russia) | plaque psoriasis, psoriatic arthritis, ankylosing spondylitis |
| Nimotuzumab | BioMab-EGFR, Theracim, Theraloc | mab | humanized | epidermal growth factor receptor (EGFR) | Y | squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma |
| Nirsevimab | | mab | human | RSV fusion glycoprotein | | respiratory syncytial virus |
| Nivolumab | Opdivo | mab | human | PD-1 | Y | cancer |
| Nofetumomab merpentan | Verluma | Fab | mouse | | | cancer (diagnosis) |
| Obiltoxaximab | Anthim | mab | chimeric | Bacillus anthracis anthrax | Y | Bacillus anthracis spores |
| Obinutuzumab | Gazyva | mab | humanized | CD20 | Y | chronic lymphatic leukemia |
| Ocaratuzumab | | mab | humanized | CD20 | | cancer |
| Ocrelizumab | Ocrevus | mab | humanized | CD20 | Y | multiple sclerosis |
| Odesivimab | | mab | human | | | part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus) |
| Odulimomab | | mab | mouse | LFA-1 (CD11a) | | prevention of organ transplant rejections, immunological diseases |
| Ofatumumab | Arzerra, Kesimpta | mab | human | CD20 | Y | chronic lymphocytic leukemia, multiple sclerosis |
| Olaratumab | Lartruvo | mab | human | PDGFRA | Y | cancer |
| Oleclumab | | mab | human | 5'-nucleotidase | | pancreatic and colorectal cancer |
| Olendalizumab | | mab | humanized | complement C5a | | systemic lupus erythematosus, lupus nephritis, acute graft-versus-host disease |
| Olokizumab | | mab | humanized | IL-6 | | rheumatoid arthritis |
| Omalizumab | Xolair | mab | humanized | IgE Fc region | Y | allergic asthma, chronic spontaneous urticaria |
| Omburtamab | | mab | mouse | CD276 | | cancer |
| OMS721 | | | human | MASP-2 | | atypical hemolytic uremic syndrome |
| Onartuzumab | | Fab | humanized | human scatter factor receptor kinase | | cancer |
| Ontuxizumab | | mab | chimeric/ humanized | TEM1 | | cancer |
| Onvatilimab | | mab | human | VISTA (protein) (VSIR) | | |
| Opicinumab | | mab | human | LINGO-1 | | multiple sclerosis |
| Oportuzumab monatox | Vicinium | scFv | humanized | EpCAM | | bladder cancer |
| Oregovomab | OvaRex | mab | mouse | CA-125 | | ovarian cancer |
| Orticumab | | mab | human | oxLDL | | |
| Otelixizumab | | mab | chimeric/ humanized | CD3 | | diabetes mellitus type 1 |
| Otilimab | | mab | human | GMCSF | | osteoarthritis, rheumatoid arthritis |
| Otlertuzumab | | mab | humanized | CD37 | | cancer |
| Oxelumab | | mab | human | OX-40 | | asthma |
| Ozanezumab | | mab | humanized | NOGO-A | | ALS and multiple sclerosis |
| Ozoralizumab | | mab | humanized | TNF-α | | inflammation |
| Pagibaximab | | mab | chimeric | lipoteichoic acid | | sepsis (Staphylococcus) |
| Palivizumab | Synagis, Abbosynagis | mab | humanized | F protein of respiratory syncytial virus | Y | respiratory syncytial virus (prevention) |
| Pamrevlumab | | mab | human | connective tissue growth factor (CTGF) | | idiopathic pulmonary fibrosis (IPF), pancreatic cancer |
| Panitumumab | Vectibix | mab | human | epidermal growth factor receptor (EGFR) | Y | colorectal cancer |
| Pankomab | | mab | humanized | tumor specific glycosylation of MUC1 | | ovarian cancer |
| Panobacumab | | mab | human | Pseudomonas aeruginosa | | Pseudomonas aeruginosa infection |
| Parsatuzumab | | mab | humanized | EGFL7 | | cancer |
| Pascolizumab | | mab | humanized | IL-4 | | asthma |
| Pasotuxizumab | | mab | chimeric/ humanized | folate hydrolase | | cancer |
| Pateclizumab | | mab | humanized | lymphotoxin alpha (LTA) | | TNF |
| Patritumab | | mab | human | ERBB3 (HER3) | | cancer |
| PDR001 | | | humanized | PD-1 | | melanoma |
| Pembrolizumab | Keytruda | mab | humanized | PD-1 | Y | melanoma and other cancers |
| Pemivibart | Pemgarda | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | US emergency use authorization (EUA) | COVID-19 |
| Pemtumomab | Theragyn | | mouse | MUC1 | | cancer |
| Perakizumab | | mab | humanized | IL-17A | | arthritis |
| Pertuzumab | Perjeta | mab | humanized | HER2/neu | Y | cancer |
| Pexelizumab | | scFv | humanized | C5 | | reduction of side effects of cardiac surgery |
| Pidilizumab | | mab | humanized | PD-1 | | cancer and infectious diseases |
| Pinatuzumab vedotin | | mab | humanized | CD22 | | cancer |
| Pintumomab | | mab | mouse | adenocarcinoma antigen | | adenocarcinoma (imaging) |
| Placulumab | | mab | human | TNF | | pain and inflammatory diseases |
| Pozelimab | Veopoz | mab | human | C5 | Y | CHAPLE disease |
| Prezalumab | | mab | human | TNF | | |
| Plozalizumab | | mab | humanized | CCR2 | | diabetic nephropathy and arteriovenous graft patency |
| Pogalizumab | | mab | humanized | tumor necrosis factor receptor (TNFR) superfamily member 4 | | |
| Polatuzumab vedotin | Polivy | mab | humanized | CD79B | Y | diffuse large B-cell lymphoma |
| Ponezumab | | mab | humanized | β-amyloid | | Alzheimer's disease |
| Porgaviximab | | mab | chimeric | Zaire ebolavirus glycoprotein | | Ebola virus disease |
| Prasinezumab | | mab | humanized | Alpha-synuclein | | Parkinson's disease |
| Prezalizumab | | mab | humanized | inducible T-cell co-stimulatory ligand (ICOSL) | | |
| Priliximab | | mab | chimeric | CD4 | | Crohn's disease, multiple sclerosis |
| Pritoxaximab | | mab | chimeric | E. coli shiga toxin type-1 | | |
| Pritumumab | | mab | human | vimentin | | brain cancer |
| PRO 140 | | | humanized | CCR5 | | HIV infection |
| Quilizumab | | mab | humanized | IGHE | | asthma |
| Racotumomab | Vaxira | mab | mouse | NGNA ganglioside | Y | non-small cell lung cancer |
| Radretumab | | mab | human | fibronectin extra domain-B | | cancer |
| Rafivirumab | | mab | human | rabies virus glycoprotein | | rabies (prophylaxis) |
| Ralpancizumab | | mab | humanized | PCSK9 | | dyslipidemia |
| Ramucirumab | Cyramza | mab | human | VEGFR2 | Y | solid tumors |
| Ranevetmab | | mab | veterinary | NGF | | osteoarthritis in dogs |
| Ranibizumab | Lucentis | Fab | humanized | VEGF-A | Y | macular degeneration (wet form) |
| Raxibacumab | | mab | human | anthrax toxin, protective antigen | Y | anthrax (prophylaxis and treatment) |
| Ravagalimab | | mab | humanized | CD40 | | Crohn's disease |
| Ravulizumab | Ultomiris | mab | humanized | C5 | Y | paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome |
| Refanezumab | | mab | humanized | myelin-associated glycoprotein | | recovery of motor function after stroke |
| Regavirumab | | mab | human | cytomegalovirus glycoprotein B | | cytomegalovirus infection |
| Regdanvimab | Regkirona | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | Y | COVID-19 |
| Relatlimab | | mab | human | LAG3 | | melanoma |
| Remtolumab | | mab | human | IL-17A, TNF | | |
| Reslizumab | Cinqair | mab | humanized | IL-5 | Y | inflammations of the airways, skin and gastrointestinal tract |
| Retifanlimab | Zynyz | mab | humanized | PD-1 | Y | Merkel cell carcinoma |
| Rilotumumab | | mab | human | hepatocyte growth factor (HGF) | | solid tumors |
| Rinucumab | | mab | human | PDGFRB | | neovascular age-related macular degeneration |
| Risankizumab | Skyrizi | mab | humanized | IL-23A | Y | Crohn's disease, psoriasis, psoriatic arthritis, and asthma |
| Rituximab | MabThera, Rituxan | mab | chimeric | CD20 | Y | lymphomas, leukemias, some autoimmune disorders |
| Rivabazumab pegol | | mab | humanized | Pseudomonas aeruginosa type III secretion system | | |
| Robatumumab | | mab | human | IGF-1 receptor (CD221) | | cancer |
| Rmab | RabiShield | | human | rabies virus G glycoprotein | Y | post-exposure prophylaxis of rabies |
| Roledumab | | mab | human | RHD (gene) (RHD) | | Rh disease |
| Romilkimab | | mab | chimeric/ humanized | IL-13 | | |
| Romosozumab | Evenity | mab | humanized | sclerostin | Y | osteoporosis |
| Rontalizumab | | mab | humanized | IFN-α | | systemic lupus erythematosus |
| Rosmantuzumab | | mab | humanized | root plate-specific spondin 3 | | cancer |
| Rovalpituzumab tesirine | | mab | humanized | DLL3 | | small cell lung cancer |
| Rovelizumab | LeukArrest | mab | humanized | CD11, CD18 | Y | haemorrhagic shock etc. |
| Rozanolixizumab | Rystiggo | mab | chimeric/ humanized | FCGRT | Y | myasthenia gravis |
| Ruplizumab | Antova | mab | humanized | CD154 (CD40L) | Y | rheumatic diseases |
| SA237 | | | humanized | IL-6 receptor | | neuromyelitis optica and neuromyelitis optica spectrum disorders |
| Sacituzumab govitecan | Trodelvy | mab | humanized | TROP-2 | Y | triple-negative breast cancer |
| Samalizumab | | mab | humanized | CD200 | | cancer |
| Samrotamab vedotin | | mab | chimeric/ humanized | LRRC15 | | cancer |
| Sarilumab | Kevzara | mab | human | IL-6 | Y | rheumatoid arthritis, ankylosing spondylitis |
| Satralizumab | Enspryng | mab | humanized | IL-6 receptor | Y | neuromyelitis optica |
| Satumomab pendetide | | mab | mouse | TAG-72 | | cancer (diagnosis) |
| Secukinumab | Cosentyx | mab | human | IL-17A | Y | uveitis, rheumatoid arthritis psoriasis |
| Selicrelumab | | mab | human | CD40 | | |
| Seribantumab | | mab | human | ERBB3 (HER3) | | cancer |
| Setoxaximab | | mab | chimeric | E. coli shiga toxin type-2 | | |
| Setrusumab | | mab | human | sclerostin (SOST) | | |
| Sevirumab | | | human | cytomegalovirus | | cytomegalovirus infection |
| Sibrotuzumab | | mab | humanized | FAP (gene) (FAP) | | cancer |
| SGN-CD19A | | mab | humanized | CD19 | | acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma |
| SHP647 | | | human | mucosal addressin cell adhesion molecule | | Crohn's disease |
| Sifalimumab | | mab | human | IFN-α | | systemic lupus erythematosus (SLE), dermatomyositis, polymyositis |
| Siltuximab | Sylvant | mab | chimeric | IL-6 | Y | cancer |
| Simtuzumab | | mab | humanized | LOXL2 | | fibrosis |
| Sipavibart | Kavigale | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | Y | COVID-19 |
| Siplizumab | | mab | humanized | CD2 | | psoriasis, graft-versus-host disease (prevention) |
| Sirtratumab vedotin | | mab | human | SLITRK6 | | cancer |
| Sirukumab | | mab | human | IL-6 | | rheumatoid arthritis |
| Sofituzumab vedotin | | mab | humanized | CA-125 | | ovarian cancer |
| Solanezumab | | mab | humanized | β-amyloid | | Alzheimer's disease |
| Solitomab | | BiTE | mouse | EpCAM | | gastrointestinal, lung, and other cancers |
| Sonepcizumab | | | humanized | sphingosine-1-phosphate | | choroidal and retinal neovascularization |
| Sontuzumab | | mab | humanized | episialin | | |
| Sotrovimab | Xevudy | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | Y | COVID-19 |
| Spartalizumab | | mab | humanized | PD-1 | | melanoma |
| Spesolimab | Spevigo | mab | humanized | Interleukin 36 receptor (IL1RL2/IL1RAP) | Y | generalized pustular psoriasis (GPP) |
| Stamulumab | | mab | human | myostatin | | muscular dystrophy |
| Sugemalimab | | mab | human | PD-1 | | non-small-cell lung cancer |
| Sulesomab | LeukoScan | Fab' | mouse | NCA-90 (granulocyte antigen) | | osteomyelitis (imaging) |
| Suptavumab | | mab | human | RSVFR | | medically attended lower respiratory disease |
| Sutimlimab | Enjaymo | mab | chimeric/ humanized | complement component 1s (C1s) | Y | cold agglutinin disease |
| Suvizumab | | mab | humanized | HIV-1 | | viral infections |
| Suvratoxumab | | mab | human | Staphylococcus aureus alpha toxin | | nosocomial pneumonia |
| Tabalumab | | mab | human | B-cell activating factor (BAFF) | | B-cell cancers |
| Tacatuzumab tetraxetan | AFP-Cide | mab | humanized | alpha-fetoprotein | | cancer |
| Tadocizumab | | Fab | humanized | integrin α$_{IIb}$β$_3$ | | percutaneous coronary intervention |
| Tafasitamab | Monjuvi | mab | humanized (from mouse) | CD19 | Y | relapsed or refractory diffuse large B-cell lymphoma |
| Talacotuzumab | | mab | humanized | CD123 | | leukemia etc. |
| Talizumab | | mab | humanized | IgE | | allergic reaction |
| Talquetamab | Talvey | BsAb | humanized | GPRC5D, CD3 | Y | relapsed or refractory multiple myeloma |
| Tamtuvetmab | Tactress | mab | veterinary | CD52 | | |
| Tanezumab | | mab | humanized | nerve growth factor (NGF) | | pain |
| Taplitumomab paptox | | mab | mouse | CD19 | | cancer |
| Tarextumab | | mab | human | Notch receptor | | cancer |
| Tarlatamab | Imdelltra | BsAb | human | DLL3, CD3 | Y | small cell lung cancer |
| Tavolimab | | mab | chimeric/ humanized | CD134 | | cancer |
| Teclistamab | Tecvayli | BsAb | human | B-cell maturation antigen (BCMA), CD3 | Y | relapsed or refractory multiple myeloma |
| Tefibazumab | Aurexis | mab | humanized | clumping factor A | | Staphylococcus aureus infection |
| Telimomab aritox | | Fab | mouse | | | |
| Telisotuzumab | | mab | humanized | HGFR | | cancer |
| Telisotuzumab vedotin | | mab | humanized | HGFR | | cancer |
| Tenatumomab | | mab | mouse | tenascin C | | cancer |
| Teneliximab | | mab | chimeric | CD40 | | autoimmune diseases and prevention of organ transplant rejection |
| Teplizumab | Tzield | mab | humanized | CD3 | Y | diabetes mellitus type 1 |
| Tepoditamab | | mab | human | dendritic cell-associated lectin 2 | | cancer |
| Teprotumumab | Tepezza | mab | human | IGF-1 receptor (CD221) | Y | thyroid eye disease |
| Tesidolumab | | mab | human | C5 | | |
| Tetulomab | | mab | humanized | CD37 | | cancer |
| Tezepelumab | Tezspire | mab | human | thymic stromal lymphopoietin (TSLP) | Y | asthma |
| TGN1412 | | | humanized | CD28 | | chronic lymphocytic leukemia, rheumatoid arthritis |
| Tibulizumab | | mab | humanized | B-cell activating factor (BAFF) | | autoimmune disorders |
| Tildrakizumab | Ilumya | mab | humanized | IL-23 | Y | immunologically mediated inflammatory disorders |
| Tigatuzumab | | mab | humanized | TRAIL-R2 | | cancer |
| Timigutuzumab | | mab | humanized | HER2 | | cancer |
| Timolumab | | mab | human | AOC3 | | |
| tiragolumab | | mab | human | | | |
| Tiragotumab | | mab | human | TIGIT | | cancer |
| Tislelizumab | | mab | humanized | PCDC1, CD279 | | non-small cell lung cancer |
| Tisotumab vedotin | Tivdak | mab | human | coagulation factor III | Y | relapsed or refractory cervical cancer |
| Tixagevimab | | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | US emergency use authorization (EUA) when used with cilgavimab | COVID-19 |
| TNX-650 | | | humanized | IL-13 | | Hodgkin's lymphoma |
| Tocilizumab | Actemra, RoActemra | mab | humanized | IL-6 receptor | Y | rheumatoid arthritis |
| Tomuzotuximab | | mab | humanized | Epidermal growth factor receptor (EGFR), HER1 | | cancer |
| Toralizumab | | mab | humanized | CD154 (CD40L) | | rheumatoid arthritis, lupus nephritis etc. |
| Tosatoxumab | | mab | human | Staphylococcus aureus | | |
| Tositumomab | Bexxar | | mouse | CD20 | Y | follicular lymphoma |
| Tovetumab | | mab | human | PDGFRA | | cancer |
| Tralokinumab | Adtralza, Adbry | mab | human | IL-13 | Y | atopic dermatitis |
| Trastuzumab | Herceptin | mab | humanized | HER2/neu | Y | breast cancer |
| Trastuzumab duocarmazine | Kadcyla | mab | humanized | HER2/neu | Y | breast cancer |
| Trastuzumab emtansine | Kadcyla | mab | humanized | HER2/neu | Y | breast cancer |
| TRBS07 | Ektomab | 3funct | | GD2 ganglioside | | melanoma |
| Tregalizumab | | mab | humanized | CD4 | | |
| Tremelimumab | Imjudo | mab | human | CTLA-4 | Y | hepatocellular carcinoma |
| Trevogrumab | | mab | human | growth differentiation factor 8 | | muscle atrophy due to orthopedic disuse and sarcopenia |
| Tucotuzumab celmoleukin | | mab | humanized | EpCAM | | cancer |
| Tuvirumab | | | human | hepatitis B virus | | chronic hepatitis B |
| Ublituximab | Briumvi | mab | chimeric | CD20 | Y | multiple sclerosis, chronic lymphocytic leukemia |
| Ulocuplumab | | mab | human | CXCR4 (CD184) | | hematologic malignancies |
| Urelumab | | mab | human | 4-1BB (CD137) | | cancer etc. |
| Urtoxazumab | | mab | humanized | Escherichia coli | | diarrhoea caused by E. coli |
| Ustekinumab | Stelara | mab | human | IL-12, IL-23 | Y | multiple sclerosis, psoriasis, psoriatic arthritis |
| Utomilumab | | mab | human | 4-1BB (CD137) | | diffuse large B-cell lymphoma |
| Vadastuximab talirine | | mab | chimeric | CD33 | | Acute myeloid leukemia |
| Vanalimab | | mab | humanized | CD40 | | |
| Vandortuzumab vedotin | | mab | humanized | STEAP1 | | cancer |
| Vantictumab | | mab | human | Frizzled receptor | | cancer |
| Vanucizumab | | mab | humanized | angiopoietin 2 | | cancer |
| Vapaliximab | | mab | chimeric | AOC3 (VAP-1) | | |
| Varisacumab | | mab | human | VEGF-A | | angiogenesis |
| Varlilumab | | mab | human | CD27 | | solid tumors and hematologic malignancies |
| Vatelizumab | | mab | humanized | ITGA2 (CD49b) | | |
| Vedolizumab | Entyvio | mab | humanized | integrin α$_4$ β$_7$ | Y | Crohn's disease, ulcerative colitis |
| Veltuzumab | | mab | humanized | CD20 | | non-Hodgkin's lymphoma |
| Vepalimomab | | mab | mouse | AOC3 (VAP-1) | | inflammation |
| Vesencumab | | mab | human | NRP1 | | solid malignancies |
| Vilobelimab | Gohibic | mab | chimeric | C5a receptor (C5a) | Y (EU), and US emergency use authorization (EUA) | COVID-19 |
| Visilizumab | Nuvion | mab | humanized | CD3 | | Crohn's disease, ulcerative colitis |
| Vobarilizumab | | scFv | humanized | IL-6 receptor | | inflammatory autoimmune diseases |
| Volociximab | | mab | chimeric | integrin α$_5$β$_1$ | | solid tumors |
| Vonlerolizumab | | mab | humanized | CD134 | | cancer |
| Vopratelimab | | mab | humanized | CD278, aka ICOS | | |
| Vorsetuzumab mafodotin | | mab | humanized | CD70 | | cancer |
| Votumumab | HumaSPECT | mab | human | tumor antigen CTAA16.88 | | colorectal tumors |
| Vunakizumab | | mab | humanized | IL-17A | | |
| Xentuzumab | | mab | humanized | IGF-1, IGF-2 | | ? |
| XMAB-5574 | | | humanized | CD19 | | diffuse large B-cell lymphoma |
| Zalutumumab | | mab | human | Epidermal growth factor receptor (EGFR) | | squamous cell carcinoma of the head and neck |
| Zanidatamab | Ziihera | BsAb | humanized | HER2, HER2 | Y | biliary tract cancer |
| Zanolimumab | | mab | human | CD4 | | rheumatoid arthritis, psoriasis, T-cell lymphoma |
| Zatuximab | | mab | chimeric | HER1 | | cancer |
| Zenocutuzumab | Bizengri | BsAb | humanized | HER2, ERBB3 (HER3) | Y | cancer |
| Ziralimumab | | mab | human | CD147 (basigin) | | |
| Zolbetuximab | Vyloy | mab | chimeric | Claudin 18 Isoform 2 | Y | gastric cancer |
| Zolimomab aritox | | mab | mouse | CD5 | | systemic lupus erythematosus, graft-versus-host disease |